Avesthagen and Manipal Acunova Announce Drug Discovery Collaboration
News May 09, 2007
Avesthagen is India’s fully integrated systems biology company that works towards the convergence of food, pharma and population genetics leading to predictive preventive personalized healthcare.
Manipal Acunova, on the other hand is a collaborative venture between the Manipal Education and Medical Group International India Private Ltd., and AcuNova Life Sciences Inc. Manipal Acunova can provide medical, clinical and project management capacities in clinical trials, lab management, data management and biostatistical services.
Avesthagen and Manipal Acunova have agreed to collaborate on providing their competencies in discovery, pre-clinical, clinical research including regulatory matters. This partnership will enable them to jointly provide a fully integrated platform from early discovery to filing approvals for new products.
Avesthagen and Manipal Acunova will also collaborate in validation of Molecular Diagnostics kits and Product Co-development for delivering high quality, affordable and advanced diagnostic tests using molecular techniques to patients and healthcare industry.
They will jointly apply and own the Intellectual Property rights to the database or samples or process or products that are created during the agreement.
Dr Villoo Morawalla Patell, Founder and Managing Director said “this is a step that Avesthagen and Manipal Acunova have taken as we both agree to provide better and efficient service to our clients as well as patients and the healthcare industry as a whole".
“The collaboration will bring in a range of services to the clients expanding to biogenerics, bionutraceuticals and biopharma companies” said Mr.D.A.Prasanna founder and Vice Chairman of Manipal Acunova Ltd.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.